Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors

被引:5
作者
Wong, Ka Kit [1 ]
Frey, Kirk A. [1 ]
Niedbala, Jeremy [1 ]
Kaza, Ravi K. [1 ]
Worden, Francis P. [2 ]
Fitzpatrick, Kellen J. [1 ]
Dewaraja, Yuni K. [1 ]
机构
[1] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Endocrine Oncol, Ann Arbor, MI 48109 USA
关键词
Ga-68-DOTATATE; Lu-177-DOTATATE; neuroendocrine tumor; PET/CT; peptide receptor radionuclide therapy; SPECT/CT; SUV; theranostics; RECEPTOR RADIONUCLIDE THERAPY; SST1-SST5; DOSIMETRY; SUBTYPES; PRRT;
D O I
10.1097/MNM.0000000000001592
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Our goal is to quantitatively compare radiotracer biodistributions within tumors and major normal organs on pretherapy Ga-68-DOTATATE PET to post-therapy Lu-177-DOTATATE single-photon emission computed tomography (SPECT) in patients receiving peptide receptor radionuclide therapy (PRRT). Methods PET/CT at similar to 60 min postinjection of Ga-68 DOTATATE and research Lu-177-SPECT/CT imaging similar to at 4h (SPECT1) and similar to 24h (SPECT2) post-cycle#1 were available. Manual contours of lesions on baseline CT or MRI were applied to co-registered SPECT/CT and PET/CT followed by deep learning-based CT auto-segmentation of organs. Tumor-to-normal organ ratios (TNR) were calculated from standardized uptake values (SUV)(mean) and SUVpeak for tumor, and SUVmean for non-tumoral liver (nliver), spleen and kidney. Results There were 90 lesons in 24 patients with progressive metastatic neuroendocrine tumor. The correlation between PET and SPECT SUV TNRs were poor/moderate: PET versus SPECT1 R-2 =0.19. 0.21, 0.29; PET versus SPECT2 R-2 =0.06, 0.16, 0.33 for TNRnliver,TNRspleen, TNRkidney, respectively. Across all patients, the average value of the TNR measured on PET was significantly lower than on SPECT at both time points (P<0.001). Using SUVmean for tumor, average TNR values and 95% confidence intervals (CI) were PET: TNRnliver =3.5 [CI: 3.0-3.9], TNRspleen =1.3 [CI. 1.2-1.5], TNRkidney = 1.7 [CI: 1.6-1.9]; SPECT1: TNRnliver = 1.0 [CI: 8.2-11.7], TNRspleen = 2.9 [CI: 2.5-3.4]. TNRkidney = 2.8 [CI: 2.3-3.3]; SPECT2: TNRnliver = 1 6.9 [CI: 1 4-1 9.9], TNRspleen =3.6 [CI: 3-4.2], TNRkidney = 3.6 [CI: 3.0-4.2]. Comparison of PET and SPECT results in a sphere phantom study demonstrated that these differences are not attributed to imaging modality. Conclusions Differences in TNR exist for the theranostic pair, with significantly higher SUV TNR on Lu-177 SPECT compared with Ga-68 PET. We postulate this phenomenon is due to temporal differences in DOTATATE uptake and internalization in tumor as compared to normal organs. (C) 2022 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:892 / 900
页数:9
相关论文
共 50 条
[31]   A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients [J].
Becx, Morticia N. ;
Minczeles, Noemie S. ;
Brabander, Tessa ;
de Herder, Wouter W. ;
Nonnekens, Julie ;
Hofland, Johannes .
CANCERS, 2022, 14 (23)
[32]   Diagnostic and Therapeutic Uptake of Intrathyroid Metastasis of Midgut Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE Imaging [J].
Racaru, Lavinia Vija ;
Sinigaglia, Mathieu ;
Fontaine, Sebastien ;
D'Aure, Dominique ;
Courbon, Frederic ;
Dierickx, Lawrence .
CLINICAL NUCLEAR MEDICINE, 2019, 44 (07) :E445-E448
[33]   Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients [J].
Pettersson, Olof ;
Fross-Baron, Katarzyna ;
Crona, Joakim ;
Sundin, Anders .
FRONTIERS IN ONCOLOGY, 2020, 10
[34]   Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors [J].
Estephany Abou Jokh Casas ;
Virginia Pubul Nú?ez ;
Urbano Anido-Herranz ;
María del Carmen Mallón Araujo ;
Maria del Carmen Pombo Pasín ;
Miguel Garrido Pumar ;
José Manuel Cabezas Agrícola ;
José Manuel Cameselle-Teijeiro ;
Ashraf Hilal ;
álvaro Ruibal Morell .
World Journal of Gastroenterology, 2020, 26 (13) :1513-1524
[35]   Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors [J].
Sandstrom, Mattias ;
Velikyan, Irina ;
Garske-Roman, Ulrike ;
Sorensen, Jens ;
Eriksson, Barbro ;
Granberg, Dan ;
Lundqvist, Hans ;
Sundin, Anders ;
Lubberink, Mark .
JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (10) :1755-1759
[36]   ACTH-Secreting Renal Neuroendocrine Tumor on 68Ga-DOTATATE PET/CT [J].
Xu, Si ;
Liu, Yang ;
Zhou, Jinxin ;
Zhang, Yifan .
CLINICAL NUCLEAR MEDICINE, 2023, 48 (04) :378-379
[37]   Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma [J].
Dadgar, Habibollah ;
Jafari, Esmail ;
Ahmadzadehfar, Hojjat ;
Rekabpour, Seyed Javad ;
Ravanbod, Mohammad Reza ;
Kalantarhormozi, Mohammadreza ;
Nabipour, Iraj ;
Assadi, Majid .
ANNALES D ENDOCRINOLOGIE, 2023, 84 (01) :45-51
[38]   Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE [J].
Pettersson, Olof Joakim ;
Fross-Baron, Katarzyna ;
Crona, Joakim ;
Sundin, Anders .
ENDOCRINE CONNECTIONS, 2021, 10 (04) :422-431
[39]   Enhancing precision: A predictive model for 177 Lu- DOTATATE treatment response in neuroendocrine tumors using quantitative 68 Ga-DOTATATE PET and clinicopathological biomarkers [J].
Akhavanallaf, Azadeh ;
Joshi, Sonal ;
Mohan, Arathi ;
Worden, Francis P. ;
Krauss, John C. ;
Zaidi, Habib ;
Frey, Kirk ;
Suresh, Krithika ;
Dewaraja, Yuni K. ;
Wong, Ka Kit .
THERANOSTICS, 2024, 14 (09) :3708-3718
[40]   Correlation study between 68Ga-DOTATOC PET/CT metrics and 177Lu-DOTATATE dosimetry for non-pancreatic neuroendocrine tumors [J].
Texier, J. S. ;
Jocmek, M. ;
Dierickx, L. ;
Vallot, D. ;
Brillouet, S. ;
Lamesa, C. ;
Courbon, F. ;
Vija, L. .
JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 :160-160